Cannabis provides a wealth of benefits to those suffering from EDS
Ehlers-Danlos syndrome (EDS) is a group of congenital and hereditary diseases based on a disorder of connective tissue synthesis. This rare disease leads, among other things, to excessive elasticity of the skin and joints as well as malformations of the cardiovascular system. The therapeutic use of cannabis can be helpful in treating the symptoms of Ehlers-Danlos syndrome, such as pain. It can also have positive effects on insomnia and depression. These are conditions that often come hand in hand with EDS.
EDS causes the connective tissue of the skin, blood vessels, and joints to underdevelop. As a result, it lacks firmness, leading to excessive stretching of the skin. In the treatment of pain, cannabinoids now have an important place as an alternative therapeutic option.
Cannabinoids provide a potential approach to pain management with a new therapeutic target and mechanism. Chronic pain often requires a polypharmaceutical approach to management, and cannabinoids are a possible addition to the variety of treatment options. Cannabinoid medications may prevent the onset of pain by slightly increasing pain thresholds.
Cannabinoids may also be an alternative to treat anxiety and depression. Of particular interest is cannabidiol (CBD), a non-psychotropic cannabinoid from the cannabis plant that has antispasmodic, anti-inflammatory, and relaxing effects. This could undoubtedly help to improve the quality of life of patients with EDS.
Cannabis and its derivative molecules have been tested due to requests for help from patients living with EDS and managing the chronic pain associated with the condition. Looking at some specific symptoms, cannabinoids could be useful for EDS sufferers due to their analgesic, anxiolytic and anti-inflammatory effects.